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Abstract
Background: Retinal neovascularization, which is the pathological growth of new blood vessels, is associated with
retinopathy of prematurity, neovascular age-related macular degeneration, diabetic retinopathy and retinal vein
occlusion. In this study, we evaluated the effect of an extract of Cnidium officinale Makino (COE) and its bioactive
compound, butylidenephthalide (BP), on the migration and tube formation of human umbilical vein endothelial cells
(HUVECs), and on retinal pathogenic neovascularization in the oxygen-induced retinopathy (OIR) mouse model.
Method: The HUVECs were incubated with COE and BP (0.1–10 μg/ml). The mice were exposed to 75 % oxygen for
5 days starting on the 7th postnatal day (P7–P12). Then, the mice were returned to room air and intraperitoneally
injected with COE (100 mg/kg) and BP (5 mg/kg) once per day for 5 days (P12–P16). On P17, we measured retinal
neovascularization and analyzed the angiogenesis-related proteins expression using protein arrays.
Results: COE and BP inhibit the HUVECs migration and the tube formation in a dose-dependent manner. In addition,
COE significantly decreased retinal neovascularization in the OIR mice. COE reduced the expression levels of AREG,
ANG, DLL4, Endostatin, IGFBP-2 and VEGF. Additionally, BP also inhibited the retinal neovascularization and down-
regulated the expression of AREG, ANG, DLL4 and VEGF.
Conclusion: These results suggest that COE and BP exerts antiangiogenic effects on retinal neovascularization by
inhibiting the expression of AREG, ANG, DLL4 and VEGF, indicating that antiangiogenic activities of COE may be in part
due to its bioactive compound, BP.
Keywords: Retinal neovascularization, Butylidenephthalide, Cnidium officinale, Oxygen-induced retinopathy, Vascular
endothelial growth factor
Background
Retinal pathological neovascularization is a central fea-
ture of retinopathy of prematurity, neovascular age-
related macular degeneration, diabetic retinopathy and
retinal vein occlusion and is the leading cause of irre-
versible blindness globally [1].
Vascular endothelial growth factor (VEGF) is a
major proangiogenic factor in retinal neovasculariza-
tion caused by hypoxia-induced retinal damage. Hypoxia
regulates sprouting angiogenesis and various proangio-
genic growth factors through multiple pathways and
increases VEGF expression at the level of gene transcrip-
tion, mRNA stability, translation, and protein secretion
levels [2, 3].
Cnidium officinale Makino, which belongs to the
Umbelliferae family, has been used as a traditional orien-
tal medicine in East Asian countries. The dried rhizomes
of C. officinale have been used in the treatment of pain,
anti-vitamin deficiency disease, menstrual disturbance,
inflammation and as a blood pressure depressant. In
addition, there are several reports suggesting that the
dried rhizomes of C. officinale have multifunctional
properties in tumor metastasis [4], angiogenesis [5],
inflammation [6] and that they have antioxidant ef-
fects [7]. Butylidenephthalide (BP) is an alkylphthalide
derived from the volatile oil of C. officinale. BP has
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antiangiogenic activities, which are associated with the ac-
tivation of the p38 and ERK1/2 signaling pathways [8]. BP
has been identified as having a variety of potential
pharmacological activities, such as anti-cancer [9], anti-
inflammatory [10], anti-platelet [11], vasorelaxant [12],
anti-anginal [13] and anti-atherosclerotic [14] effects.
We have previously reported that Samul-tang; a mix-
ture of four herbs, including Angelicae gigantis, Cnidium
officinale, Paeonia lactiflora, and Rehmannia glutinosa;
has an inhibitory effect on the retinal pathogenic angio-
genesis induced by ischemic retinopathy in OIR mice
[15]. Although the antiangiogenic properties of C.
officinale and its bioactive ingredient, BP, have been
reported, the effect on retinal pathogenic neovasculariza-
tion in the oxygen-induced retinopathy (OIR) mouse
model is still unknown. Therefore, in this study, we
investigated the inhibitory effect of the extract of C.
officinale, one of the four components of Samul-tang
and its bioactive compound, BP on the migration and
tube formation by HUVECs, and on retinal pathogenic
neovascularization in the oxygen-induced retinopathy
(OIR) mouse model.
Methods
Preparation of Cnidium officinale
A standardized COE was purchased from a plant
extract bank at the Korea Research Institute of
Bioscience & Biotechnology (Daejeon, Korea). A col-
lection of voucher specimens is available for confirm-
ation in the plant extract bank (Korea Research
Institute of Bioscience and Biotechnology, Daejeon,
Korea). Briefly, dried and grinded C. officinale rhi-
zomes (4.6875 g) waere boiled with distilled water at
100 °C for 2 h, and the extract was filtered, lyophi-
lized (yield: 33.3 %). COE was standardized using a
reference compounds, butylidenephthalide (Sigma, MO,
USA), by high performance liquid chromatography
(HPLC).
The wound healing migration assay
Human umbilical vein endothelial cells (HUVECs) were
purchased from Cell Systems (Kirkland, WA, USA) and
were taken from passages 3 to 6 in this study. HUVECs
were seeded at 3.5 × 105 cells/well in 12-well culture
plates (Nalgene Nunc, NY, USA) and cultured in
medium for 24 h. Confluent HUVECs were wounded
with pipette tips. After the wounding, the plates were
rinsed with a serum-free medium, and treated with COE
(0.1–10 μg/ml) or BP (0.1–10 μg/ml) for 12 h. The cells
were observed under a light microscope (BX51; Olympus,
Tokyo, Japan) and photographed in triplicate at 200×
magnification. Cell migration was determined by counting
the number of cells that moved beyond the reference line
in randomly selected fields.
The tube formation assay
Tissue culture plates were coated with 400 μL of growth
factor–reduced basement membrane matrix (Matrigel;
Becton Dickenson, Franklin Lakes, NJ, USA). HUVECs
were seeded at 1 × 105 cells/well in 24-well culture plates
(Nalgene Nunc, NY, USA) and treated with EGM-2
media containing COE (0.1–10 μg/ml) or BP (0.1–
10 μg/ml) for 17 h. The tubes formed was observed
under a light microscope and photographed at 200×
magnification. Tube formation was quantified by manu-
ally counting the branching points of capillary-like struc-
tures per visual field.
An oxygen-induced retinopathy(OIR) mouse model
Ischemic retinopathy was induced in C57BL/6 mouse
pups, as previously described [16]. On the 12th postnatal
day (P12), after being exposed to 75 ± 2 % oxygen for
5 days (P7–P12), the mice were randomly assigned to
one of three groups: the OIR, COE (100 mg/kg/day) or
BP (5 mg/kg/day) group. The normal control group
(Nor) was maintained under room air from birth until
the 17th postnatal day (P0 to P17). To minimize the dif-
ferences in the weights of the pups, one mouse nursed
6–8 pups, and low-weight pups were discarded from the
data sets. The COE and BP were dissolved in 5 %
DMSO-containing saline immediately before use, and
100 μl of this solution was injected intraperitoneally
once per day for 5 days (P12–P16). The Nor and OIR
groups were injected with same volume of vehicle solu-
tion for 5 days. On P17, after 5 days of intraperitoneal
injections, the mice were anesthetized and sacrificed.
These experiments were repeated four times using four
animals in each group. In our previous study, COE and
BP prevented subretinal neovascularization in an animal
model of laser-induced choroidal neovascularization
[17]. The effective doses of COE and BP were
100 mg/kg and 5 mg/kg, repectively. Based on our
previous findings, the doses of COE and BP in OIR
mice were determined. All experiments that used ani-
mals were approved by the Institutional Animal Care
and Use Committee of the Korea Institute of Oriental
Medicine (Daejeon, Korea).
Fluorescein-dextran microscopy and lectin staining
On P17, the mice in each group were anesthetized with
zolazepam (Zoletil, Virbac, Carros, France). PBS contain-
ing fluorescein-dextran (FD40S, Sigma, MO, USA).was
subsequently circulated through the left ventricle. The
retinas were dissected, flat mounted onto glass slides
and viewed using fluorescence microscopy (BX51,
Olympus, Tokyo, Japan). The non-perfusion area in
the retina were measured in flat mounts labeled with
fluorescein-dextran The neovascular tufts in the ret-
ina were measured in flat mounts labeled with
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tetramethylrhodamine isothiocyanate (TRITC)-conjugated
isolectin B4 (Sigma, MO, USA). The retinas were incu-
bated with 1 % bovine serum albumin and 5 % Triton X-
100 in PBS for 3 hours at room temperature.The retinas
were washed 3 times with PBS and incubated over-
night at 4 °C with Bandeiraea simplicifolia isolectin
B4 (Sigma-Aldrich, MO, USA) diluted 1:50 in PBS.
The retinas were washed with 0.05 % Tween 20 in
PBS, followed by incubation with streptavidin TRITC
(1:500, Serotec, Oxford, UK) for 4 h at 37 °C. The
neovascular tufts was viewed with an Olympus BX51
microscope (Olympus, Tokyo, Japan). Quantification
of the non-perfusion area and neovascular tufts in the
retina was quantified using ImageJ software (NIH,
MD, USA).
Angiogenesis-related protein array
To investigate angiogenesis-related proteins in the retinas,
a mouse angiogenesis array (R&D Systems, MN, USA)
was performed according to the manufacturer’s protocol.
Briefly, the retinas (n = 3) were homogenized in PBS using
protease inhibitors and centrifuged at 10,000 x g for 5 mi-
nutes, and 250 ug of total protein concentrations were
quantified. The lysates were added to a membrane spotted
with antibodies against angiogenesis-related proteins.
After being incubated overnight at 4 °C, the membranes
were treated with streptavidin-horseradish peroxidase and
were visualized using an enhanced chemiluminescence de-
tection system (Amersham Bioscience, NJ, USA) on an
image analyzer (LAS-3000, Fujifilm, Tokyo, Japan).
Optical density measurements were obtained using the
ImageJ software (NIH, MD, USA).
Real-time PCR analysis
Total RNA was isolated using the TRIzol reagent
(Invitrogen, CA, USA), and 0.5 μg of total RNA was re-
verse transcribed into cDNA with the PrimeScript First
Strand cDNA Synthesis kit (Bio-Rad, CA, USA). Real-
time quantitative PCR was performed with specific
primers for VEGF and GAPDH using an iQ5 Continu-
ous Fluorescence Detector System (Bio-Rad, CA, USA).
The sequences of the primers were as follows: for VEGF,
5′-TCC TCC TAT CTC CAC CAC CTA TCC-3′ and
5′-GAC CCA GCC AGC CAT ACC C-3′; and for
GAPDH, 5′-AAC GAC CCC TTC ATT GAC-3′ and 5′-
TCC ACG ACA TAC TCA GCA C-3′. All real-time
PCR experiments were run in triplicate. The mRNA
levels of GAPDH were determined for the normalization
of the VEGF mRNA expression values using the iQ5 op-
tical system software (Bio-Rad, CA, USA).
Statistical analysis
The results were expressed as the mean ± SE and were
analyzed using one-way analysis of variance (ANOVA)
followed by Tukey’s multiple comparison tests or using
unpaired Student’s t-tests. All analyses were performed
using the Prism 6.0 software (GraphPad Software, San
Diego, CA, USA).
Results
COE and BP inhibits migration and tube formation of
HUVECs
COE and BP have an inhibitory effect against the migra-
tion of HUVECs. As shown in Fig. 1, COE inhibited the
HUVEC migration distance by approximately 94.6 ±
2.4 %, 92.0 ± 6.3 % and 87.0 ± 15.9 % at 0.1, 1 and 10 μg/
ml doses, respectively. In addition, BP (10 μg/ml) also
inhibited the HUVEC migration distance more potently
than COE (65.76 ± 0.79 %). We next examined the in-
hibitory effects of COE and BP on the tube formation of
HUVECs. The HUVECs plated on matrigel formed a
massive network of tubes after 17 h, which was dis-
rupted by COE and BP treatment (0.1–10 μg/ml). As
shown in Fig. 2, COE treatment slightly changed the
tube formation compared with the control group. How-
ever, BP treatment markly inhibited the tube formation
by approximately 91.3 ± 16.2 %, 87.9 ± 9.8 % and 83.4 ±
14.7 % at 0.1, 1 and 10 μg/ml doses, respectively. In our
unpublished data, the quantity of BP in COE were
0.21 ± 0.01 mg/g. Thus, the total BP content is 2.1 ±
0.1 ng/ml in 10 μg/ml of COE. This concentration for
10 μg/ml of BP is equal to 47 mg/ml of COE. Therefore,
activities of COE at the concentration of 10 μg/ml were
weaker than those of BP at same concentration in the
endothelial cell migration assay and tube formation assay.
These results clearly showed that COE and BP treatment
inhibit motility and tubular structure formation as well as
disrupts the preformed capillary tubes by HUVECs.
COE inhibits retinal neovascularization
The OIR mice that were treated with COE exhibited a
significant decrease in the pathological changes that oc-
curred during ischemic retinopathy. As shown in Fig. 3,
COE decreased the area of vascular obliteration of the
central retina and prevented pathogenic retinal neovas-
cularization compared with the OIR group on P17. Mice
that were treated with 100 mg/kg of COE had signifi-
cantly decreased non-perfused areas compared with the
OIR group (Fig. 3a). In addition, COE considerably de-
creased the formation of neovascular tufts (by 30.69 %)
compared with the OIR group (Fig. 3c). Consequently,
COE helped prevent the pathogenic retinal neovasculari-
zation during ischemic retinopathy.
COE regulates the expression of angiogenesis-related
factors
We investigated the expression levels of angiogenesis-
related factors in the retina using a protein array to
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evaluate the direct effects of COE on OIR. As shown in
Fig. 4, COE decreased the expression of proangiogenic
factors (i.e., amphiregulin (AREG), angiogenin (ANG),
delta like ligand 4 (DLL4), insulin-like growth factor
binding protein-2 (IGFBP-2) and VEGF) in a dose-
dependent manner compared with saline-treated OIR
mice. These results indicate that COE might exert anti-
angiogenic effects by inhibiting the expression of AREG,
ANG, DLL4, IGFBP-2 and VEGF.
BP blocks retinal neovascularization
BP is one of the major compounds found in C. officinale.
To determine whether BP has a preventive effect against
pathological retinal neovascularization, this compound
was also administered in the OIR mouse model. As
shown in Fig. 5, mice that were treated with 5 mg/kg of
BP failed to exhibit a significant change in the area of
non-perfusion in the center of the retina (Fig. 5a), but
BP significantly reduced the formation of neovascular
tufts (by 43.59 %) compared with the OIR group (Fig. 5c).
These results indicate that BP is a potent antiangiogenic
bioactive compound of C. officinale
BP also regulates the expression of angiogenesis-related
factors, similar to those observed in the COE-treated mice
In the protein array, BP decreased the expression of
proangiogenic factors (i.e., AREG, ANG, DLL4,
interleukin-1 alpha (IL-1α) and VEGF) in a dose-
dependent manner compared with saline-treated OIR
mice (Fig. 6). These results suggest that BP mediated
antiangiogenic effects by inhibiting the expression of
ARED, ANG, DLL4 and VEGF, indicating that the
Fig. 1 The effect of COE and BP on the migration of human umbilical vein endothelial cells. a COE and BP suppressed migration in HUVECs in
the wound healing assay. The cells were treated with COE and BP and incubated at 37 °C. After 12 h, the number of cells that had migrated into
the scratched area was calculated. b The bar graph represents the quantification of migrated cells from the untreated control, the COE-treated
and the BP-treated groups. The data are presented as the mean ± SE. (n = 3; * p < 0.001 vs. the control group)
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Fig. 2 The effect of COE and BP on tube formation of human umbilical vein endothelial cells. a Matrigel (400 μL) was added to 24-well plates
and allowed to solidify for 1 h at 37 °C. HUVECs were treated with COE and BP in VEGF-containing EGM-2 media and incubated at 37 °C. After
17 h, randomly chosen fields were photographed under light microscope. b The bar graph represents the quantification of tube formation of the
control group, the COE-treated and BP-treated groups. The data are presented as the mean ± SE. (n = 3; * p < 0.05 vs. the control group)
Fig. 3 The effect of COE on retinal neovascularization in OIR mice. a The retinal blood vessels were visualized via fluorescein angiography using
FITC-dextran. Nor, normal control mice; OIR, saline-treated OIR mice and COE, OIR mice treated with 100 mg/kg of COE. b The quantification
results are expressed as the percentage of the central nonperfused area within the total retinal area. c The retinal neovascular tufts were visualized
using isolectin B4 staining. Nor, normal control mice; OIR, saline-treated OIR mice; COE, OIR mice treated with 100 mg/kg of COE. d The quantification
results are expressed as neovascular tufts on the retina surface. The bar graph values represent the mean ± SE (n = 5; *p < 0.05 vs. the saline-treated
OIR mice)
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antiangiogenic activities of COE may be in part due
to its bioactive compound, BP.
COE and BP treatmemt downregulates VEGF mRNA
expression
In antibody array, the expression levels of various angio-
genic factors were changed by COE or butylidene-
phthalide. However, when considering 1.5-fold change
thresholds, VEGF only displayed a >1.5-fold up-regulation
in the vehicle-treated rats and a <1.5-fold down-regulation
in the COE as well as butylidenephthalide-treated group.
Thus, to confirm the change of VEGF expression levels in
the retina, we examined the induction of VEGF mRNA
using real-time PCR. As expected, we observed a robust
induction of VEGF mRNA during oxygen-induced retin-
opathy. However, the VEGF levels were significantly de-
creased in COE and BP treated OIR mice (Fig. 7).
Discussion
Retinal neovascularization is a major cause of blindness
worldwide. Various therapeutic strategies such as laser
photocoagulation, photodynamic therapy, and anti-VEGF
therapy result in the regression of the retinal neovas-
cularization. However, these retinal neovascularization
therapies are limited and have severe undesirable side
effects [18]. Thus, it is necessary to develop better
retinal neovascularization treatment therapeutic tar-
gets. In the present study, we evaluated the antiangio-
genic effects of Cnidium officinale and its bioactive
compound, BP, during pathological retinal neovascu-
larization in OIR mice.
The OIR model has been widely used as a valuable
tool in retinal neovascularization pathogenesis research
[19]. In the mouse OIR model, the hyperoxic phase (P7–
P12) results in the loss of immature vessels in the cen-
tral retina and the development of vaso-obliteration.
When the mice are returned to room air (P12–P17), the
retina becomes hypoxic due to the absence of the retinal
vasculature, which stimulates proangiogenic factors and
results in abnormal neovascularization [20]. Many previ-
ous studies using the OIR model have demonstrated the
valuable effect of this model and have laid the founda-
tion for today’s clinical application of antiangiogenic
treatments in retinal neovascularization [19, 20].
Fig. 4 The expression of retinal angiogenesis-related proteins in OIR mice. Expression of proangiogenic and antiangiogenic factors in the retina
were analyzed using protein arrays and quantified using ImageJ software. Proteins for which expression was modulated in COE-treated retinas are
indicated by numbers. Nor, normal control mice; OIR, saline-treated OIR mice and COE, OIR mice treated with 100 mg/kg COE. 1: AREG, amphiregulin;
2: ANG, angiogenin; 3: DLL4, Delta like ligand 4; 4: IGFBP-2, insulin-like growth factor binding protein 2; 5: VEGF: Vascular endothelial growth factor. The
bar graph values represent the mean ± SE (n = 3; #p < 0.05 vs. the normal control mice, *p < 0.05 vs. the saline-treated OIR mice)
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The neovascular processes occurring in OIR include
pathogenic preretinal neovascular formations and intrar-
etinal revascularization. In our study, COE potently
inhibited neovascular tuft formation and enhanced re-
vascularization of deep retinal vascular plexuses. Al-
though this accelerated retinal revascularization effect of
COE that accompanied its potent angiostatic activity
was surprising, such dual properties (angiostasis of
pathologic neovascularization and facilitation of physio-
logical revascularization) have been also shown in sev-
eral anti-anigiogenic agents. Banin et al. showed that
T2-TrpRS (carboxyl-terminal fragment of tryptophan
tRNA Synthetase) that not only inhibit pathologic neo-
vascularization, but also facilitate physiological revascu-
larization of ischemic retinal tissue [21]. Wang et al. also
showed that tenomodulin (a novel member of the tumor
necrosis factor family) similarly reducing preretinal neo-
vascular tuft formation and enhance revascularization of
the obliterated areas [22]. The mechanism of dual ac-
tions of these agents remains unclear. Angiogenesis is a
complex process regulated by an intricate balance of
stimulators and inhibitors. Multiple signaling pathways
converge to regulate the growth of new blood vessels
during both physiological and pathologic neovasculariza-
tion, and some factors have demonstrated seemingly
conflicting, environmentally dependent roles in this
complex process. Although both processes proceed by
angiogenesis, physiological vascular development is highly
controlled and occurs under moderate levels of hypoxia
[23], whereas pathogenic neovascularization in OIR oc-
curs in a highly hypoxic environment [24]. The apparent
paradoxical effects of COE could be reflect different
microenvironment-dependent activities. Another possible
explanation is that VEGF in intraocular angiogenesis was
markedly upregulated in the aqueous humor and vitreous
body [25]. This feature suggests that anti-angiogenic activ-
ity by COE was seen in the avascular parts, such as aque-
ous humor, and vitreous body.
The proliferation and migration of capillary endothelial
cells are critical for blood vessel development and are reg-
ulated by proangiogenic and antiangiogenic agents [26].
VEGF plays a major role in stimulating endothelial cell
proliferation and migration and acts a crucial role in
angiogenesis. VEGF expression is known to be inhibited
by hyperoxia [27]. Upon termination of hyperoxia expos-
ure, hypoxia-driven vascular proliferation is induced, and
VEGF expression is greatly upregulated to a higher level
[28, 29]. Several studies suggested that VEGF expression
is upregulated in the retina and vitreous of patients or the
model animals with ischemic retinopathies [30, 31]. Clin-
ical evidence has suggested that using of VEGF or VEGFR
inhibitors, provide great benefits in patients with ROP,
neovascular AMD and diabetic retinopathy. The mono-
clonal anti-VEGF antibody bevacizumab and the tyrosine
Fig. 5 The effect of BP on retinal neovascularization in OIR mice. a The retinal blood vessels were visualized via fluorescein angiography using
FITC-dextran. Nor, normal control mice; OIR, saline-treated OIR mice and BP, OIR mice treated with 5 mg/kg of BP. b The quantification results are
expressed as the percentage of the central nonperfused area within the total retinal area. c The retinal neovascular tufts were visualized using
isolectin B4 staining. Nor, normal control mice; OIR, saline-treated OIR mice and BP, OIR mice treated with 5 mg/kg of BP. d The quantification
results are expressed as neovascular tufts on the retina surface. The bar graph values represent the mean ± SE (n = 5; *p < 0.01 vs. the saline-treated
OIR mice)
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kinase inhibitors sorafenib and sunitinib are the first FDA
approved antiangiogenic drugs that prevent the growth of
new blood vessels [7]. However, increasing evidence sug-
gests that AREG, ANG and DLL4 also have a role in ret-
inal neovascularization. Our protein array indicated that
COE and BP markedly suppressed the expression of
AREG, ANG DLL4 and VEGF. AREG, an epidermal
growth factor receptor ligand, is regulated by prolyl-4-
hydroxylase domain enzyme 2 (PHD2), a regulator of the
stability of HIF-1α that is involved in tumor progression
[32] and angiogenesis [33]. AREG has been shown to pro-
mote the proliferation of airway epithelial and smooth
muscle cells and mucin gene expression [34]. Neutralization
of AREG also prevents cultured endothelial cells from
forming tubes [35]. ANG has been found to be increased in
the vitreous of patients with diabetic retinopathy [36] and
contributes to aberrant intrapulmonary neovascularization
and remodeling [6]. The DLL4/Notch signaling pathway
Fig. 6 The expression of retinal angiogenesis-related proteins in OIR mice. Proteins for which expression was modulated in BP-treated retinas are
indicated by numbers. Nor, normal control mice; OIR, saline-treated OIR mice and BP, OIR mice treated with 5 mg/kg of BP. 1: AREG, amphiregulin;
2: ANG, angiogenin; 3: DLL4, Delta like ligand 4; 4:IL-1α, interleukin-1 alpha; 5: VEGF: Vascular endothelial growth factor. The bar graph values
represent the mean ± SE (n = 3; #p < 0.05 vs. the normal control mice, *p < 0.05 vs. the saline-treated OIR mice)
Fig. 7 Real-time PCR analysis of VEGF mRNA levels in OIR mice. When compared with the normal controls, the VEGF group mRNAs were
dramatically increased in the retinas of OIR mice and markedly reduced after COE (a) or BP (b) treatment. Nor, normal control mice; OIR, saline-
treated OIR mice; COE, OIR mice treated with COE (100 mg/kg); and BP, OIR mice treated with BP (5 mg/kg). The data are shown as the mean ±
SE (n = 6; #p < 0.001 vs. the normal control mice, *p < 0.05, **p < 0.01 vs. the saline-treated OIR mice)
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might play an important role in the HIF-1α-VEGF pathway
in the regulation of the progression of CNV under hypoxic
conditions [37]. It has also been reported that the up-
regulation of DLL4 by VEGF is mediated by both VEGFR1
and VEGFR2, which is dependent on the phos-
phatidylinositol 3-kinase/Akt pathway but not MAPK/
ERK or Src kinases [38].These findings suggest that
COE and its bioactive compound, BP elicit antiangio-
genic activities by inhibiting the expressions of AREG,
ANG and DLL4.
COE is known to have beneficial pharmacological ac-
tivities in various experimental models. The anti-tumor
and anti-metastatic effects of COE might be mediated by
its angiogenic activities against neovascularization [39].
COE displays anti-cancer properties by inducing apop-
tosis via the downregulation of Sp1 in HSC-2 human
oral cancer cells and cell cycle arrest in HT29 human
colorectal cancer cells [5, 40]. Our results showed that
COE and its bioactive compound, BP, exhibited potent
efficiency in suppressing HUVEC migration and tube
formation. In addition, the effects of COE and BP are
mediated not only by VEGF but also by AREG, ANG
and DLL4. VEGF plays a major role in retinal neovascu-
larization. However, other angiogenic signaling factors
may also be involved in retinal neovascularization. Our
previous studies have shown that drugs targeting mul-
tiple factors have more potent antiangiogenic activities
[15, 41]. Therefore, these observations suggest that
COE and BP are promising agents that may block
retinal neovascularization by inhibiting multiple an-
giogenic factors.
Although, BP is a bioactive ingredient of COE, other
various compounds, such as ferulic acid, falcarindiol;
6-hydroxy-7-methoxydihydroligustilide; ligustilidiol and
senkyunolide H have beed indentified in COE [42]. COE
reduced non-perfused areas in the OIR mice, but BP failed
to decrease avascular areas. A possible explanation is that
herbal extracts are known to have various advantages of
synergy and interactions among the various phytochemi-
cals. Yang et al. showed that ferulic acid demonstrated in-
hibition of endothelial cell proliferation, migration and
tube formation [43]. These findings suggest that the
inhibitory effect of COE may be a result from synergistic
interactions of these compounds.
Conclusion
COE and BP have potent efficiency in inhibiting endo-
thelial cell migration and tube formation, which are the
critical steps in angiogenesis. COE and BP exhibited an
antiangiogenic effects by suppressing the expression of
AREG, ANG, DLL4 and VEGF in a retinal neovasculari-
zation mouse model. Therefore, COE may serve as a
valuable herbal medicine in the treatment of human is-
chemic retinopathy.
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